Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 11Gastrointestinal 11Head & Neck 7Endocrine 7Dermatologic 5CNS 5Breast 5Sarcoma 4Lymphoid 4Tumor-Agnostic 3Other hematologic neoplasm 2NET 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 1Carcinoma 1

Interventions

trastuzumab deruxtecan 1pembrolizumab 1lenvatinib 1larotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Neoplasms × Tumor-Agnostic × Clear all
NCT02637687 2025-06-22

SCOUT

Bayer

Phase 1/2 Active not recruiting
154 enrolled 2 FDA
Tumor-Agnostic

Neoplasms

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Daiichi Sankyo

Phase 1 Completed
292 enrolled 35 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡